From AI to Lp(a): AHA president reflects on cardiology’s hottest topics
American Heart Association (AHA) President Manesh Patel, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2026 about some of the biggest trends on display at the meeting.
Patel, chief of cardiology and vice president of heart and vascular services at Duke Health, said artificial intelligence (AI), precision medicine, heart failure, arrhythmia management, preventive cardiology and cardiometabolic disease were just some of the conference's hottest topics.
AHA Scientific Sessions 2026 featured landmark clinical trials across multiple areas of cardiology. AI took a prominent role, with an entire late-breaking clinical trial session dedicated to evaluating the use of the technology in cardiovascular care.
Beyond AI, Patel pointed to growing interest in understanding the underlying biology of cardiovascular disease and developing more targeted treatments. This includes research into genomics, Mendelian randomization and precision medicine approaches that could help identify which therapies are most appropriate for individual patients.
He also highlighted the continued convergence of cardiovascular, kidney and metabolic disease research. Three major contributors to lifetime cardiovascular risk are cumulative exposure to elevated low-density lipoprotein (LDL) cholesterol, high blood pressure and obesity. Patel said new therapies targeting these risk factors are creating significant opportunities to reduce cardiovascular disease.
AI adoption requires evidence and implementation standards
AI was one of the most visible technology trends at the meeting, with numerous companies showcasing FDA-cleared algorithms on the expo floor. Patel said the challenge is shifting from developing and approving AI tools to determining how they should be incorporated into routine clinical practice.
"The thing we need to focus on is the gap between what's proven and what people are getting," Patel explained. "The greatest discoveries in health must reach people where they are. And AI has a huge opportunity to do that, but only if we can actually study it, regulate it, and deploy it."
He said it is fantastic that AI tools are getting regulatory approval, but what happens next understanding how you put it into practice. AI could help close the gap in healthcare disparities, but only if the technology is properly evaluated and deployed in a trusted manner.
With multiple vendors offering algorithms for similar applications, hospitals also need ways to compare products and determine which ones are appropriate for their needs. Patel pointed to AHA initiatives designed to help address this challenge, including AI testing environments that allow healthcare organizations to evaluate different algorithms using common datasets. AHA highlighted its AI Torch program that may offer a test setting that provides a standardized way to compare tools. Patel said future efforts will need to address clinical integration and broader networks for studying AI performance over time.
Lp(a) research remains an important area of investigation
Another major topic at the meeting was lipoprotein(a), or Lp(a), an inherited cardiovascular risk factor that has attracted increasing attention as pharmaceutical companies develop therapies to lower its levels. Patel noted the substantial interest surrounding the late-breaking Lp(a) HORIZON trial evaluating the drug pelacarsen. While treatment did lower Lp(a) by 78%, it did not have any impact on the time to occurrence of a major adverse cardiovascular event (MACE).
Patel said these results raise important scientific questions about Lp(a) that still need to be addressed.
Patients who have had elevated Lp(a) levels for decades may respond differently to treatment initiated after a cardiovascular event than individuals treated earlier in the disease process, he explained. In addition, Patel believes other ongoing clinical trials for other Lp(a) drugs should continue to be evaluated because they may help identify the appropriate patient populations and treatment strategies.
Training and access will determine the impact of new technologies
Patel also highlighted a presentation by cardiologist Eric Topol, MD, director and founder of the Scripps Research Translational Institute, on the future of cardiology. That session explored the relationship between human intelligence and artificial intelligence and how the two could work together to improve patient care.
Emerging technologies could provide clinicians with better tools to examine patients, identify disease and guide treatment decisions. However, Patel said access, education and training will be critical to translating these capabilities into better outcomes. He cautioned against assuming that the availability of new technology automatically leads to its adoption. Sometimes the tools need improvement, while in other cases clinicians need better training and established pathways for incorporating them into practice.
As an interventional cardiologist, Patel compared the challenge to introducing a new catheter technology. Even if the catheter offers capabilities that could improve a procedure, physicians must learn how to use it effectively before patients can benefit. The same principle applies to AI and other emerging cardiovascular technologies. Developing and approving tools is only part of the process. Ensuring clinicians know when and how to use them, identifying the right patients, and establishing evidence-based implementation strategies will ultimately determine their impact.
For Patel, the overarching challenge facing cardiology is making sure that scientific breakthroughs translate into meaningful improvements in care and reach the patients who need them.